Top-line data expected in Q2 2024 SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company, along with Mundipharma, has completed enrollment in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis.

预计2024年第二季度的顶级数据圣地亚哥，2023年12月6日（环球通讯社）--Cidara Therapeutics，Inc.（纳斯达克：CDTX），一家旨在挽救生命和提高面临严重疾病患者护理标准的生物技术开发疗法，今天宣布该公司与Mundipharma，已经完成了在中国进行的3期ReSTORE试验的登记，该试验评估了热扎芬净治疗念珠菌病和侵袭性念珠菌病的疗效和安全性。

The portion of the trial conducted in China included 52 patients diagnosed with candidemia and/or invasive candidiasis. ReSTORE (NCT03667690) is a global, randomized, double-blind, controlled Phase 3 pivotal clinical trial evaluating the efficacy and safety of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin, the current standard of care, to treat patients with candidemia and/or invasive candidiasis.  “The completion of this trial enrollment marks a significant step in our efforts to bring an important treatment option to patients living with difficult to treat candidemia and invasive candidiasis,” said Taylor Sandison, M.D., MPH, chief medical officer of Cidara.

“Rezafungin has demonstrated its benefit for patients in the U.S. and E.U., and now there is the potential to target an even broader global patient population who are suffering and in need of a new treatment option.” Jeffrey Stein, Ph.D., president and chief executive officer of Cidara stated, “We appreciate the hard work of our investigators involved in this trial, and the patients who have helped us achieve this key milestone.

“Rezafungin已证明其对美国和欧盟患者有益，现在有可能针对更广泛的全球患者人群，这些患者正在遭受痛苦并需要新的治疗选择。”Cidara总裁兼首席执行官Jeffrey Stein博士表示，“我们感谢参与这项试验的研究人员的辛勤工作，以及帮助我们实现这一关键里程碑的患者。

Our team looks forward to the availability of the results of this study in the second quarter of next year and the potential to expand the reach of this treatment for patients. M.

我们的团队期待着在明年第二季度获得这项研究的结果，并有可能扩大这种治疗对患者的影响。M。